SHARx Urges HR and CFO Leaders to Rethink the True Cost of Pharmacy Benefits

As prescription spending continues to squeeze benefits budgets, SHARx says employers should measure the consequences in compensation, hiring, retention, and employee trust, not pharmacy costs alone.

Rising prescription drug costs and usage are creating consequences far beyond the pharmacy benefit line item, putting pressure on employers’ ability to invest in compensation, hiring, and other benefits, according to Paul Pruitt, Chief Growth Officer and Co-Founder of SHARx, a procurement management solution for high-cost prescription drugs. The company is urging HR and finance leaders to treat pharmacy strategy as a workforce and business issue rather than a narrow procurement decision.